Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kythera Biopharmaceuticals Inc Announces Proposed Public Offering of Common Stock


Monday, 7 Oct 2013 04:02pm EDT 

Kythera Biopharmaceuticals Inc announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intends to use the net proceeds of the offering to fund the ongoing development and preparation for potential commercialization of ATX-101, including the preparation and submission of its New Drug Application, or NDA, for ATX-101, and the balance for working capital and general corporate purposes, including research and development. J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers, and representatives of the underwriters for the offering. Leerink Swann LLC is also acting as a joint book-running manager. Cowen and Company, LLC is acting as co-manager. KYTHERA intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold to cover over-allotments, if any. 

Company Quote

34.55
0.17 +0.49%
22 Aug 2014